TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12 months~* Men and women must agree to follow methods of contraception~Exclusion Criteria:~* Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator~* Known immunocompromised status or any disease or condition which might compromise participant safety~* Prior exposure to BMS-986263~* Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests~* Hepatic decompensation~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dose A BMS-986263 (Type: EXPERIMENTAL): None
- Dose B BMS-986263 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk Ewing's Family of tumors (metastatic disease at diagnosis, humerus, femur or trunk primary, bulky primary (greater than 8 cm)), or LDH greater or equal to 900 IU/ml prior to biopsy.~* No prior chemotherapy.~* Written informed consent~* Normal cardiac function (ejection fraction greater or equal to 50%).~* Males and non pregnant females.~* Biologic age 3-60 years old.~* Adequate bone marrow function (defined as an absolute peripheral granulocyte count of\>500/mm3, platelet count of \>75,000/mm3, and hemoglobin \>8g/dl with transfusion if required).~* Adequate renal function defined as blood urea nitrogen (BUN) \<30mg% and serum creatinine \<1.5 x normal for age or creatinine clearance \>70.~* Patients of child bearing potential must agree to use an effective method of contraception.~* Normal hepatic function (bilirubin \<1.5mg/dl, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \<3x normal).~Exclusion Criteria: N/A

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: VACdxr With ImmTher (Type: EXPERIMENTAL): Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days. Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
- Arm B: VACdxr (Type: ACTIVE_COMPARATOR): Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days, Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \<35%~* QRS time ≥150ms LBB~* NYHA classification ≥ NYHA III~* permanent (\> 6 months) Atrial Fibrillation~* sinus rhythm (control group)~* Condition after Implantation of a Medtronic CRT device~* written informed consent~Exclusion Criteria:~* exchange of the current CRT device~* mitral incompetence (2. degree)~* no compliance~* participation in another study~* pregnancy~* patients with AV node~* patients after heart transplant or those who are on the transplant list

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AV ablation (Type: EXPERIMENTAL): None
- Rate control (Type: ACTIVE_COMPARATOR): Rate control by drugs
- Sinus rhythm (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented classical Hodgkin lymphoma according to the WHO Classification. Nodular lymphocyte predominant Hodgkin lymphoma is excluded~* No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma~* Measurable disease must be present either on physical examination or imaging studies. Any tumor mass measurable in two dimensions and \> 2 cm is acceptable (or 1.5 cm if 0.5 cm slices are used as in spiral CT scans)~* Age ≥ 18~* Patients must have at least one hypermetabolic lesion identifiable on initial PET scan~* LVEF by ECHO or MUGA within institutional normal limits~* Initial laboratory data should be compatible with the administration of standard doses of ABVD chemotherapy~Exclusion Criteria:~* Patient has no known HIV infection~* Patient is non-pregnant and non-lactating. Due to the teratogenic potential of the agents used in this study, pregnant or nursing women may not be enrolled. Women and men of reproductive potential should agree to use an effective means of birth control~* No other history of lymphoproliferative disorder or granulomatous disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Stage Disease (Type: OTHER): Group A
- Advance Stage Disease (Type: OTHER): Group B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent before start of study-related assessments or procedures~* Diagnosis of axSpA (either ankylosing spondylitis or non-radiographic axSpA) and fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axSpA~* Participants aged ≥ 18 years~* Disease duration \< 5 years~* Participants must have a Baseline disease activity as defined by an ASDAS ≥ 2.1 or a Bath AS Disease Activity Index (BASDAI) ≥ 4~* NSAID-naive or not treated with the maximal recommended NSAID dose during the last 2 weeks prior to the Baseline visit~* Participants must never have failed a NSAID taken at maximal recommended dose for 2 weeks or more.~Exclusion Criteria:~* Contraindications for NSAIDs or tumor necrosis factor (TNF) blocker according to local labeling~* If entering the study on concomitant NSAIDs, participants taking the maximal recommended dose during the last 2 weeks prior to the Baseline Visit or have failed or developed intolerance to a NSAID taken at maximal recommended dose for 2 weeks or more at any time~* Prior exposure to any anti-TNF therapy; any biologic therapy with a potential therapeutic impact on SpA, or participant has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treat-to-Target (T2T) (Type: EXPERIMENTAL): Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
- Standard of Care (SOC) (Type: ACTIVE_COMPARATOR): Participants received treatment as prescribed by their physician according to the local standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between the age of 18 and 80 years old~* diagnosed with preoperative anemia, defined as hemoglobin \<13.0 grams per deciliter (g/dL)~* scheduled for elective cardiac surgery (CABG, valve, or CABG/valve), including both first time and repeat procedures~* documented negative pregnancy test within 7 days prior to the procedure for females of child-bearing potential~* a written informed consent prior to any procedure, using a form that is approved by the UT Southwestern Institutional Review Board~* agreement to be compliant~Exclusion Criteria:~* uncontrolled hypertension (defined as systolic pressure greater than 180 millimeters of mercury (mmHg), diastolic pressure greater than 100mmHg, not adequately controlled by anti-hypertensive therapy at the time of procedure)~* current renal failure on dialysis or serum creatinine \>3.0 milligrams per deciliter (mg/dL)~* unstable angina (defined by chest pain and EKG changes indicating ischemia at rest)~* thromboembolism within the past year~* current active primary or metastatic malignancy or history of myeloid malignancy~* seizures within the past year~* history of stroke within the last 6 months~* patients who have platelet count lower than 50,000 per cubic millimeter (mm3) or coagulation abnormality~* sepsis or bacteremia defined by positive blood culture~* patients who have known hypersensitivity to EPO or any of its components~* patients who have known hypersensitivity to Feraheme or any of its components~* patients who refuse blood transfusion, (i.e. Jehovah's Witnesses)~* pregnant or breast feeding~* patients who are unable to provide informed consent or who has inability to understand or corporate with study procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EPO and Feraheme (Type: ACTIVE_COMPARATOR): Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
- Control (Type: NO_INTERVENTION): The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anesthesia Geriatric Evaluation and Quality of Life After Peripheral Vascular Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 70 years or older~* Mentally competent~* Planned peripheral vascular surgery of the lower limb (femoral artery desobstruction, bypass surgery, amputation), possibly combined with endovascular procedure~* Signed informed consent

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Training for Stroke Neurorehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 or older~* Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) that occurred more than 6 months before entering the study~* Presence of voluntary hand activity indicated by a score of at least 1 on the finger mass extension/grasp release item of the Fugl-Meyer Test of Motor Function~* Adequate cognitive status, as determined by clinical evaluation~* No upper extremity injury or conditions that limited use prior to the stroke~Exclusion Criteria:~* Cannot give informed consent~* Have clinically significant fluctuations in mental status within a month of enrollment~* Were not independent prior to the stroke as measured by scores \<95 on the Barthel Index or \>1 on the Modified Rankin Scale~* Have hemispatial neglect as determined by \>3 errors on the Star Cancellation Test~* Have severe sensory loss as determined by a score of 2 on the sensory item of the NIHSS~* Receiving oral or injected antispasticity medications during study treatment~* Pain that interferes with daily activities~* History of prior stroke

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Robotic (Type: EXPERIMENTAL): The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
- Conventional (Type: ACTIVE_COMPARATOR): Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Significant nausea/vomiting~* Failed maxeran and domperidone~* Underlying treatment of causes has failed~* Adequate cognitive function~* Communicates well~Exclusion Criteria:~* Partial/complete bowel obstruction~* Currently taking Haldol or olanzapine~* Has drug induced extrapyramidal symptoms~* Parkinson's disease~* Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Online Video Counselling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently residing in Australia~* Eligible to receive support from the Veterans and Veterans Families Counselling Service (VVCS)~* Aged between 18 and 65~* Home access to broadband internet~* Own a device (e.g., computer, laptop, or tablet) that has a webcam and can support videoconferencing~* Be able to reasonably travel to a VVCS centre to access counselling~* Referred for one-to-one counselling or therapy~* Be willing and able to receive either modality of treatment (i.e., online or in-person counselling).~Exclusion Criteria:~* Not currently residing in Australia~* Not eligible to receive support from VVCS~* Significant current risk issues or levels of acute distress requiring crisis management~* Current serving member of the Australian Defence Force with a high security clearance (above Baseline Vetting)~* Referred for couple or family counselling.~* Have received a psychiatric diagnosis of post-traumatic stress disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Traditional in-person (Type: ACTIVE_COMPARATOR): Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
- Online counselling (Type: EXPERIMENTAL): Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age \>22~2. Ability to consent to study.~3. Symptoms of neuropathic corneal pain for at least 3 months, such as burning, stinging, light sensitivity, discomfort or pain.~4. Positive in vivo confocal microscopy (IVCM) findings for NCP such as presence of microneuromas and decreased nerve density.~5. Fifty percent or more relief of pain or discomfort after instillation of Proparacaine eye drops as measured by the Visual Analogue Scale (VAS).~Exclusion Criteria:~1. Clinically significant acute ocular surface diseases, such as active infectious keratitis or recent ocular surgery in the past 3 months.~2. Chronic or recurrent epistaxis, coagulation disorders.~3. Nasal or sinus surgery or significant trauma to the nose.~4. Severe nasal airway obstruction or vascularized nasal polyps.~5. Cardiac demand pacemaker, implanted defibrillator, or other implanted electronic device in the head or neck.~6. Chronic or recurrent nosebleeds~7. Bleeding disorder~8. Known hypersensitivity (allergy) to the hydrogel material~9. Disabling arthritis, neuropathy, or limited motor coordination affecting self-handling of the device.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years~* histologically confirmed breast cancer or colorectal cancer~* Patient starting oral treatment : capecitabine alone or in combination with lapatinib (can be included before the first cycle or during the first 2 cycles).~* Volunteer to participate in the study.~* ambulatory treated patient~* Able to read, write and understand French.~* Subject who accept to use MEMS monitors to automatically compile their drug dosing histories~* Written informed consent~Exclusion Criteria:~* more than 3 metastatic chemotherapies~* any severe concomitant condition which makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capecitabine (Type: OTHER): patients treated by capecitabine alone (n=100)
- capecitabine + lapatinib (Type: OTHER): patients treated by capecitabine and lapatinib (n=100)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy